All Articles

Real-world clinical practice data indicate that telotristat ethyl (TE) use in patients with progressive neuroendocrine tumors (NETs) may provide clinical benefit in terms of improvements in carcinoid syndrome (CS) symptoms, functional status, and weight. Read More ›

Safety analysis data of concomitant telotristat ethyl (TE) plus peptide receptor radionuclide therapy (PRRT) in patients with metastatic/nonresectable neuroendocrine tumors (NETs) and carcinoid syndrome diarrhea (CSD) indicate that the safety profile of combination treatment was consistent with individual TE and PRRT therapies. Read More ›

Results of the TELEPRO-II study showed that telotristat ethyl (TE) treatment resulted in significant, clinically relevant improvements across carcinoid syndrome (CS) symptoms in a real-world setting. Read More ›

Findings of a retrospective analysis suggest that patients with well-differentiated metastatic/unresectable grade 3 gastroenteropancreatic neuroendocrine tumors (GEP-NETs) may derive modest progression-free survival (PFS) benefit with somatostatin analog (SSA) monotherapy. Read More ›

Findings of a comparative real-world analysis of long-acting somatostatin analogs (SSAs) indicate that lanreotide was associated with lower injection burden, use of rescue medications, and cost. Read More ›

Results of the randomized, open-label phase 2 Australasian Gastrointestinal Trials Group CONTROL NET study indicate that capecitabine/temozolomide (CAPTEM) plus ¹⁷⁷Lu-octreotate peptide receptor radionuclide therapy (PPRT) combination treatment was active and well-tolerated compared with CAPTEM or PPRT alone in patients with pancreatic neuroendocrine tumors (pNETs) and updated midgut neuroendocrine tumors (mNETs). Read More ›

Real-world data from a retrospective analysis of octreotide long-acting release (LAR) dosing patterns on treatment persistence in patients with symptomatic metastatic neuroendocrine tumors (NETs) indicate that physician experience and treatment at tertiary centers has a significant impact on dose selection and treatment persistence. Read More ›

Findings of a comparative retrospective analysis indicate that first-line octreotide long-acting release (LAR) and lanreotide treatment was associated with similar progression-free survival (PFS) and biochemical response in patients with metastatic, well-differentiated metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Read More ›

Results of a placebo-controlled, randomized phase 2 trial indicate that maintenance treatment with lanreotide autogel (LAN) following first-line treatment may provide clinical benefit in aggressive grade 1 and 2, well-differentiated, duodeno-pancreatic neuroendocrine tumors (NETs). Read More ›

Read More ›